

Jan Novak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6803273/publications.pdf>

Version: 2024-02-01

150
papers

13,355
citations

22548

61
h-index

26792

111
g-index

154
all docs

154
docs citations

154
times ranked

10228
citing authors

#	ARTICLE	IF	CITATIONS
1	IgA vasculitis with nephritis: update of pathogenesis with clinical implications. <i>Pediatric Nephrology</i> , 2022, 37, 719-733.	0.9	35
2	Immunoglobulin A nephropathy is characterized by anticomensal humoral immune responses. <i>JCI Insight</i> , 2022, 7, .	2.3	13
3	208 Identification of <i>Trichomonas vaginalis</i> 5-nitroimidazole resistance targets to inform future drug development. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 32-32.	0.3	0
4	Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1629-1636.	0.4	5
5	Cytokines and Production of Aberrantly O-Glycosylated IgA1, the Main Autoantigen in IgA Nephropathy. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 301-315.	0.5	4
6	Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases. <i>Glycobiology</i> , 2021, 31, 540-556.	1.3	7
7	Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. <i>Journal of Autoimmunity</i> , 2021, 118, 102593.	3.0	27
8	Transcription Factor β -Catenin Plays a Key Role in Fluid Flow Shear Stress-Mediated Glomerular Injury in Solitary Kidney. <i>Cells</i> , 2021, 10, 1253.	1.8	4
9	Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor-Mediated AXL Phosphorylation. <i>Kidney Medicine</i> , 2021, 3, 1003-1013.e1.	1.0	2
10	Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know. <i>Journal of Clinical Medicine</i> , 2021, 10, 3467.	1.0	24
11	IgA glycosylation and immune complex formation in IgAN. <i>Seminars in Immunopathology</i> , 2021, 43, 669-678.	2.8	33
12	Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4501.	1.0	30
13	Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 726215.	2.2	9
14	Immunoglobulin A Glycosylation and Its Role in Disease. <i>Experientia Supplementum (2012)</i> , 2021, 112, 433-477.	0.5	7
15	IgA Vasculitis with Nephritis in Adults: Histological and Clinical Assessment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4851.	1.0	3
16	TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. <i>Kidney International</i> , 2020, 97, 340-349.	2.6	78
17	Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?. <i>Journal of Nephrology</i> , 2020, 33, 307-316.	0.9	14
18	Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. <i>IScience</i> , 2020, 23, 101711.	1.9	4

#	ARTICLE	IF	CITATIONS
19	A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in <i>Trichomonas vaginalis</i> . <i>Parasitology</i> , 2020, 147, 1383-1391.	0.7	26
20	P0473LONGITUDINAL CHANGES OF IGA1 O-GLYCOFORM IN IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
21	Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins. <i>Expert Review of Proteomics</i> , 2020, 17, 275-296.	1.3	8
22	Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 168-180.	1.2	26
23	Upregulated proteoglycan-related signaling pathways in fluid flow shear stress-treated podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F312-F322.	1.3	6
24	Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation. <i>Scientific Reports</i> , 2020, 10, 671.	1.6	18
25	Distinct Fcγ receptor N-glycans modulate the binding affinity to immunoglobulin A (IgA) antibodies. <i>Journal of Biological Chemistry</i> , 2019, 294, 13995-14008.	1.6	29
26	Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2017-2026.	3.0	72
27	Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis. <i>Kidney International Reports</i> , 2019, 4, 1717-1724.	0.4	22
28	Glycosylation in health and disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 346-366.	4.1	1,166
29	The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. <i>Frontiers in Immunology</i> , 2019, 10, 504.	2.2	100
30	Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. <i>PLoS ONE</i> , 2019, 14, e0212254.	1.1	29
31	IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2. <i>Glycobiology</i> , 2019, 29, 543-556.	1.3	9
32	Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles. <i>Journal of Virology</i> , 2019, 93, .	1.5	15
33	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
34	Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 461-476.	0.6	61
35	Secondary IgA nephropathy. <i>Kidney International</i> , 2018, 94, 674-681.	2.6	79
36	Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients. <i>BioTechniques</i> , 2018, 65, 71-77.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE, 2018, 13, e0190967.	1.1	56
38	Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2017, 28, 1943-1950.	3.0	46
39	What insights can proteomics give us into IgA nephropathy (Berger's disease)?. Expert Review of Proteomics, 2017, 14, 645-647.	1.3	4
40	Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney International Reports, 2017, 2, 1194-1207.	0.4	49
41	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	3.0	174
42	Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls. International Journal of Nephrology, 2017, 2017, 1-5.	0.7	8
43	GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genetics, 2017, 13, e1006609.	1.5	92
44	Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. Disease Markers, 2016, 2016, 1-9.	0.6	21
45	Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?. Disease Markers, 2016, 2016, 1-6.	0.6	32
46	The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Frontiers in Immunology, 2016, 7, 117.	2.2	123
47	SP135ANTIGLYCAN IGG AUTOANTIBODY PREDICTS THE OXFORD CLASSIFICATION SCORES S AND T IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2016, 31, i130-i131.	0.4	0
48	Markers for the progression of IgA nephropathy. Journal of Nephrology, 2016, 29, 535-541.	0.9	66
49	IgA nephropathy enigma. Clinical Immunology, 2016, 172, 72-77.	1.4	24
50	IgA nephropathy. Nature Reviews Disease Primers, 2016, 2, 16001.	18.1	322
51	Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 3278-3284.	3.0	27
52	Heterogeneity of Aberrant O-Glycosylation of IgA1 in IgA Nephropathy. , 2016, , 53-68.		1
53	IgA Nephropathy and Related Diseases. , 2015, , 2023-2038.		5
54	Current Understanding of the Role of Complement in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 1503-1512.	3.0	236

#	ARTICLE	IF	CITATIONS
55	The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2015, 89, 6782-6791.	1.5	5
56	New Insights into the Pathogenesis of IgA Nephropathy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 8-18.	1.2	54
57	Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1195-1204.	3.0	124
58	N-Acetylgalactosaminide α 2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 234-238.	0.4	29
59	Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy following Tonsillectomy and Steroid Therapy. <i>PLoS ONE</i> , 2014, 9, e89707.	1.1	72
60	A Panel of Serum Biomarkers Differentiates IgA Nephropathy from Other Renal Diseases. <i>PLoS ONE</i> , 2014, 9, e98081.	1.1	93
61	Cytokines Alter IgA1 O-Glycosylation by Dysregulating C1GalT1 and ST6GalNAc-II Enzymes. <i>Journal of Biological Chemistry</i> , 2014, 289, 5330-5339.	1.6	123
62	Immune profile of IgA-dominant diffuse proliferative glomerulonephritis. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 479-483.	1.4	5
63	Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	24
64	Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 770-777.	0.7	59
65	Development of animal models of human IgA nephropathy. <i>Drug Discovery Today: Disease Models</i> , 2014, 11, 5-11.	1.2	24
66	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	9.4	505
67	HIV-1 Envelope Glycan Moieties Modulate HIV-1 Transmission. <i>Journal of Virology</i> , 2014, 88, 14258-14267.	1.5	20
68	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. <i>AIDS Research and Therapy</i> , 2014, 11, 23.	0.7	29
69	The Combined Role of Galactose-Deficient IgA1 and Streptococcal IgA-binding M Protein in Inducing IL-6 and C3 Secretion from Human Mesangial Cells: Implications for IgA Nephropathy. <i>Journal of Immunology</i> , 2014, 193, 317-326.	0.4	47
70	The genetics and immunobiology of IgA nephropathy. <i>Journal of Clinical Investigation</i> , 2014, 124, 2325-2332.	3.9	182
71	Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy. <i>PLoS ONE</i> , 2014, 9, e99026.	1.1	28
72	The Kinetics of Glomerular Deposition of Nephritogenic IgA. <i>PLoS ONE</i> , 2014, 9, e113005.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: Role of cysteine alkylation during sample processing. <i>Journal of Proteomics</i> , 2013, 92, 299-312.	1.2	48
74	Biomarkers in IgA nephropathy: relationship to pathogenetic hits. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 615-627.	1.6	55
75	Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 829-839.	2.4	55
76	Pathogenesis of Immunoglobulin A Nephropathy: Recent Insight from Genetic Studies. <i>Annual Review of Medicine</i> , 2013, 64, 339-356.	5.0	108
77	IgA Nephropathy: Molecular Mechanisms of the Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 217-240.	9.6	116
78	Pathogenesis of immunoglobulin A nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 287-294.	1.0	20
79	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. <i>PLoS Genetics</i> , 2012, 8, e1002765.	1.5	301
80	Autoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1579-1587.	3.0	209
81	The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. <i>Kidney International</i> , 2012, 82, 1284-1296.	2.6	75
82	Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy. <i>International Journal of Nephrology</i> , 2012, 2012, 1-7.	0.7	17
83	Development of a Model of Early-Onset IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1364-1374.	3.0	51
84	In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. <i>Results in Immunology</i> , 2012, 2, 166-172.	2.2	32
85	The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. <i>Kidney International</i> , 2012, 82, 790-796.	2.6	185
86	Production of N-acetylgalactosaminyl-transferase 2 (GalNAc-T2) fused with secretory signal IgI ⁹ in insect cells. <i>Protein Expression and Purification</i> , 2012, 81, 175-180.	0.6	11
87	Determination of Severity of Murine IgA Nephropathy by Glomerular Complement Activation by Aberrantly Glycosylated IgA and Immune Complexes. <i>American Journal of Pathology</i> , 2012, 181, 1338-1347.	1.9	42
88	Naturally Occurring Structural Isomers in Serum IgA1 O-Glycosylation. <i>Journal of Proteome Research</i> , 2012, 11, 692-702.	1.8	68
89	Glycosylation of IgA1 and pathogenesis of IgA nephropathy. <i>Seminars in Immunopathology</i> , 2012, 34, 365-382.	2.8	110
90	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	1.7	151

#	ARTICLE	IF	CITATIONS
91	Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy. <i>Clinical Nephrology</i> , 2012, 78, 465-469.	0.4	8
92	The Pathophysiology of IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1795-1803.	3.0	584
93	Aberrant Glycosylation of IgA1 and Anti-Glycan Antibodies in IgA Nephropathy: Role of Mucosal Immune System. <i>Advances in Oto-Rhino-Laryngology</i> , 2011, 72, 60-63.	1.6	40
94	Membrane-Assisted Online Renaturation for Automated Microfluidic Lectin Blotting. <i>Journal of the American Chemical Society</i> , 2011, 133, 19610-19613.	6.6	31
95	Genome-wide association study identifies susceptibility loci for IgA nephropathy. <i>Nature Genetics</i> , 2011, 43, 321-327.	9.4	528
96	Galactosylation of Serum IgA1 O-Glycans in Celiac Disease. <i>Journal of Clinical Immunology</i> , 2011, 31, 74-79.	2.0	7
97	IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3451-3457.	0.4	64
98	Oxidative Stress and Galactose-Deficient IgA1 as Markers of Progression in IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1903-1911.	2.2	102
99	Reevaluation of the Mucosa-Bone Marrow Axis in IgA Nephropathy with Animal Models. <i>Advances in Oto-Rhino-Laryngology</i> , 2011, 72, 64-67.	1.6	12
100	Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. <i>Kidney International</i> , 2011, 80, 79-87.	2.6	205
101	Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. <i>Journal of Clinical Investigation</i> , 2011, 121, 3991-4002.	3.9	208
102	Pathogenesis of Henoch-Schönlein purpura nephritis. <i>Pediatric Nephrology</i> , 2010, 25, 19-26.	0.9	125
103	Genetic studies of IgA nephropathy: past, present, and future. <i>Pediatric Nephrology</i> , 2010, 25, 2257-2268.	0.9	77
104	Comparison of Methods for Profiling O-Glycosylation. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 719-727.	2.5	136
105	Galactose-Deficient IgA1 in African Americans with IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2069-2074.	2.2	73
106	Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody Recognition. <i>Journal of Biological Chemistry</i> , 2010, 285, 20860-20869.	1.6	131
107	Clustered O-Glycans of IgA1. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2545-2557.	2.5	86
108	Tissue distribution and biological activities of immune complexes are determined by their size and composition. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1007-1007.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1708-1713.	0.4	18
110	Recognition of Galactose-Deficient <i>O</i> -Glycans in the Hinge Region of IgA1 by <i>N</i> -Acetylgalactosamine-Specific Snail Lectins: A Comparative Binding Study. <i>Biochemistry</i> , 2010, 49, 5671-5682.	1.2	33
111	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	2.5	434
112	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	5.8	273
113	Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1029-1043.	0.8	66
114	Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. <i>Journal of Clinical Investigation</i> , 2009, 119, 1668-77.	3.9	356
115	IgA Immune-Complex. , 2009, , 177-191.		7
116	IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA Nephropathy. <i>Seminars in Nephrology</i> , 2008, 28, 78-87.	0.6	173
117	Analysis of IgA1 <i>N</i> -Glycosylation and Its Contribution to Fc γ RI Binding. <i>Biochemistry</i> , 2008, 47, 11285-11299.	1.2	66
118	Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2384-2395.	3.0	160
119	Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1008-1014.	3.0	227
120	IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. <i>Journal of Clinical Investigation</i> , 2008, 118, 629-39.	3.9	217
121	IgA Nephropathy and Henoch-Schoenlein Purpura Nephritis: Aberrant Glycosylation of IgA1, Formation of IgA1-Containing Immune Complexes, and Activation of Mesangial Cells. <i>Contributions To Nephrology</i> , 2007, 157, 134-138.	1.1	97
122	Advances in Urinary Proteome Analysis and Biomarker Discovery. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1057-1071.	3.0	264
123	IgA Nephropathy: Characterization of IgG Antibodies Specific for Galactose-Deficient IgA1. , 2007, 157, 129-133.		25
124	IgA Nephropathy: Current Views of Immune Complex Formation. , 2007, 157, 56-63.		19
125	IgA Nephropathy: A Clinical Overview. , 2007, 157, 19-26.		11
126	Identification and Characterization of CMP-NeuAc:GalNAc-IgA1 \pm 2,6-Sialyltransferase in IgA1-producing Cells. <i>Journal of Molecular Biology</i> , 2007, 369, 69-78.	2.0	44

#	ARTICLE	IF	CITATIONS
127	Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. <i>Molecular Immunology</i> , 2007, 44, 2598-2604.	1.0	80
128	Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. <i>Electrophoresis</i> , 2007, 28, 4469-4483.	1.3	83
129	The genetics of IgA nephropathy. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 325-338.	2.0	64
130	Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 389, 1397-1407.	1.9	85
131	Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. <i>World Journal of Urology</i> , 2007, 25, 467-476.	1.2	48
132	Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. <i>Pediatric Nephrology</i> , 2007, 22, 2067-2072.	0.9	122
133	IgA-containing immune complexes in the urine of IgA nephropathy patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2478-2484.	0.4	50
134	Immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis. , 2006, , 213-221.		1
135	Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. <i>Aids</i> , 2005, 19, 381-389.	1.0	100
136	IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. <i>Kidney International</i> , 2005, 67, 504-513.	2.6	184
137	Determination of Aberrant O-Glycosylation in the IgA1 Hinge Region by Electron Capture Dissociation Fourier Transform-Ion Cyclotron Resonance Mass Spectrometry. <i>Journal of Biological Chemistry</i> , 2005, 280, 19136-19145.	1.6	125
138	Glycosylation and Size of IgA1 Are Essential for Interaction with Mesangial Transferrin Receptor in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 622-634.	3.0	160
139	IgA nephropathy: an update. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 171-179.	1.0	88
140	The Fap1 fimbrial adhesin is a glycoprotein: antibodies specific for the glycan moiety block the adhesion of <i>Streptococcus parasanguis</i> in an in vitro tooth model. <i>Molecular Microbiology</i> , 2002, 43, 147-157.	1.2	83
141	Interactions of human mesangial cells with IgA and IgA-containing immune complexes1. <i>Kidney International</i> , 2002, 62, 465-475.	2.6	117
142	Pathogenic potential of galactose-deficient IgA1 in IgA nephropathy. <i>Nephrology</i> , 2002, 7, S92-S99.	0.7	6
143	Pathogenic potential of galactose-deficient IgA1 in IgA nephropathy. <i>Nephrology</i> , 2002, 7, S92.	0.7	7
144	Progress in molecular and genetic studies of IgA nephropathy. <i>Journal of Clinical Immunology</i> , 2001, 21, 310-327.	2.0	98

#	ARTICLE	IF	CITATIONS
145	Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. FEBS Journal, 2000, 267, 6810-6816.	0.2	39
146	Detection of Antimicrobials in Bee Products with Activity Against Viridans Streptococci. Journal of Alternative and Complementary Medicine, 2000, 6, 383-389.	2.1	26
147	Heterogeneity of O-glycosylation in the hinge region of human IgA1. Molecular Immunology, 2000, 37, 1047-1056.	1.0	65
148	Authors' reply:. American Journal of Kidney Diseases, 2000, 35, 555-556.	2.1	4
149	Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. , 2000, 267, 6810.		1
150	Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. Journal of Clinical Investigation, 1999, 104, 73-81.	3.9	406